West Pharmaceutical (WST) Q1 2026 earnings review
High-Value Products Explode, SmartDose Divested, Earnings Surge
West delivered an exceptional Q1 2026, obliterating expectations with organic revenue accelerating to 15.3% and Adjusted EPS skyrocketing 46.9% YoY. Destocking is officially dead; the company is now riding a massive demand wave for High-Value Products (HVP) driven by GLP-1 volumes and Annex 1 regulatory conversions. Crucially, management solved a major margin headache by agreeing to sell the SmartDose 3.5mL asset to AbbVie. Driven by this momentum, management confidently raised FY26 top and bottom-line guidance. The only blemish on a pristine income statement is a sharp drop in operating cash flow, driven by a massive spike in accounts receivable.
🐂 Bull Case
HVP Components and HVP Delivery Devices grew 22.6% and 27.5% organically. GLP-1 and Biologics demand is structurally outstripping historical growth rates, pulling overall corporate margins upward.
The sale of the SmartDose 3.5mL system to AbbVie purifies the portfolio. Management had struggled with this asset's profitability and automation costs; divesting it is an immediate win for the margin profile.
🐻 Bear Case
Despite Net Income soaring 54% YoY, Operating Cash Flow fell 30% due to a $100M+ spike in Accounts Receivable. Revenue growth is heavily tying up cash.
The Standard Products segment grew a meager 0.5% organically. While West is intentionally driving mix-shift toward HVP, stagnation in a segment representing nearly 20% of sales acts as an anchor.
⚖️ Verdict: 🟢🟢
Bullish. The 15.3% organic growth print proves the destocking narrative is fully in the rearview mirror. With the SmartDose overhang removed and FY26 guidance raised across the board, the fundamental growth algorithm is executing flawlessly.
Key Themes
HVP Components Leading Accelerating Growth
High-Value Product (HVP) Components—representing 48% of total revenue—accelerated massively, printing 22.6% organic growth YoY. This compares to a mid-single-digit guide in early 2025. Management credits double-digit growth in both GLP-1 and non-GLP-1 volumes. The sustained tailwinds of European Annex 1 conversions and Biologics recovery have created a structural acceleration in the core business.
SmartDose Divestiture to AbbVie
West is selling its SmartDose 3.5mL On-Body Delivery System to AbbVie, expecting a mid-2026 close. This is a highly strategic positive. In 2025, management repeatedly noted they were 'evaluating all options' for SmartDose due to margin pressures and the need for costly automated manufacturing lines. Removing this $55M (H2 25 run-rate) lower-margin business purifies the margin profile.
Cash Flow Diverging from Net Income
A major red flag exists on the cash flow statement. While Net Income surged 54% YoY to $138.8M, Operating Cash Flow reversed, falling 30% to $89.9M (from $129.4M a year ago). The culprit is working capital: Accounts Receivable spiked by $111.2M sequentially to $685.6M. This massive cash drain implies collections are lagging the aggressive revenue ramp. If not a simple timing issue, this could signal stretched customer payment terms.
European Capacity Generating Returns
Revenue in Europe, Middle East, and Africa (EMEA) grew a blistering 17.9% organically (30.1% reported). Throughout 2025, West aggressively hired and trained personnel to alleviate manufacturing constraints at its European HVP plants. This quarter's regional breakout validates that the capacity bottlenecks have been shattered and production is successfully matching demand.
Standard Products Stagnation
Standard Products organic growth was essentially stable but flat, crawling at 0.5%. While the long-term strategy correctly involves cannibalizing standard components in favor of HVP via Annex 1 upgrades, this segment still makes up 19% of total sales. Near-zero growth here mutes the company's overall top-line potential.
Aggressive Share Repurchases Executed
Management executed heavily on their capital return promises, buying back 1.2 million shares for $297.6M in Q1 at an average price of $243.57. For context, they only repurchased $133.5M in 25Q1 and $134.0M in all of FY25. This 2.2x increase in buyback velocity signals extreme confidence in the underlying cash generation of the core HVP business.
Other KPIs
Accelerating. Up 190 basis points from 33.2% a year ago. This reflects exceptional positive operating leverage and mix-shift as higher-margin HVP components and Delivery Devices dramatically outpace Standard Products.
Decelerating. Down from $58.1 million in 25Q1. Despite capital expenditures dropping from $71.3M to $42.7M YoY, FCF was pressured entirely by the aforementioned working capital drag in Accounts Receivable.
Stable. Organic growth of 6.2% is solid. Note that the segment name changed from 'Contract-Manufactured Products' to better align with the strategic shift toward obesity/diabetes self-injection devices and drug handling.
Guidance
Accelerating. Raised from prior $3.215-$3.275B. The midpoint ($3.32B) implies 8.0% YoY reported growth and 8.0% organic growth. Crucially, this guidance removes $55M in H2 SmartDose revenues, making the underlying core raise even stronger than it appears.
Accelerating. Raised from prior $7.85-$8.20. Midpoint of $8.57 implies 17.6% YoY growth versus FY25's $7.29, driven by gross margin expansion and the removal of the margin-dilutive SmartDose segment.
Decelerating sequentially. The $840M midpoint implies a slight sequential drop from Q1's $844.9M, but represents 8.3% reported and 8.3% organic YoY growth. This reflects typical seasonality and tougher base effects from Q2 2025.
Stable. The $2.08 midpoint represents 13.0% YoY growth vs $1.84 in 25Q2. It is slightly below the $2.13 printed in Q1 2026, aligning with the sequential revenue guidance.
Key Questions
Accounts Receivable Spike
Accounts receivable surged by over $110 million sequentially, severely impacting Q1 Operating Cash Flow despite record earnings. Is this merely the timing of billings at the end of the quarter, or have customer payment terms been extended to win volume?
Post-SmartDose Device Strategy
With the SmartDose 3.5mL asset being sold to AbbVie, how should we view the remainder of the HVP Delivery Device portfolio? Are there other margin-dilutive legacy assets currently under strategic review?
Standard Products Strategy
Standard Products grew just 0.5% organically. Are we nearing the terminal run-rate for this segment as Annex 1 systematically cannibalizes standard packaging, or are there competitive pressures causing market share loss at the lower end?